Epiglottitis medical therapy: Difference between revisions
Sergekorjian (talk | contribs) |
Sergekorjian (talk | contribs) |
||
Line 34: | Line 34: | ||
:::*Alternate regimen (1): [[Levofloxacin]] 750 mg IV q24h {{and}} [[Clindamycin]] 600–1200 mg IV q6–12h | :::*Alternate regimen (1): [[Levofloxacin]] 750 mg IV q24h {{and}} [[Clindamycin]] 600–1200 mg IV q6–12h | ||
:*'''2. Pathogen-directed antimicrobial therapy''' | :*'''2. Pathogen-directed antimicrobial therapy''' | ||
::*'''2.1 Streptococcus pneumoniae''' | |||
::*'''2.2 Streptococcus pyogenes''' | |||
::*'''2.3 Streptococcus agalactiae''' | |||
::*'''2.4 Streptococcus anginosus''' | |||
::*'''2.5 Staphylococcus aureus''' | |||
::*'''2.6 Haemophilus influenzae''' | |||
::*'''2.7 Klebsiella pneumoniae''' | |||
::*'''2.8 Moraxella catarrhalis''' | |||
::*'''2.9 Neisseria spp.''' | |||
::*'''2.10 Pasteurella multocida''' | |||
::*'''2.11 Pseudomonas aeruginosa''' | |||
::*'''2.12 Candida albicans''' | |||
==Pathogen-Based Therapy== | ==Pathogen-Based Therapy== |
Revision as of 17:24, 5 October 2015
Epiglottitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Epiglottitis medical therapy On the Web |
American Roentgen Ray Society Images of Epiglottitis medical therapy |
Risk calculators and risk factors for Epiglottitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]
Overview
Epiglottitis is a medical emergency and warrants immediate establishment of a patent airway. Once the airway has been secured, cultures of blood and epiglottic surface should be obtained before administration of antimicrobial therapy. An appropriate antibiotic regimen that covers Streptococcus pneumoniae, beta-hemolytic streptococci, and Staphylococcus aureus includes parenteral Cefotaxime or Ceftriaxone in combination with Vancomycin (or Levofloxacin in combination with Clindamycin for Penicillin-allergic patients). Adjuvant therapy is commonly used in the management of stridor associated with acute epiglottitis. Adjuvant therapy includes corticosteroids and racemic Epinephrine.
Principles of Therapy for Acute Epiglottitis
Antibiotic Therapy
- In view of the emergence of Streptococcus pneumoniae, beta-hemolytic streptococci, and ampicillin-resistant Haemophilus influenzae as the most common causative bacteria of acute epiglottitis, empiric therapy with a third-generation cephalosporin (such as cefotaxime and ceftriaxone) or ampicillin-sulbactam is recommended.[1]
- An anti-staphylococcal agent (such as vancomycin or clindamycin) should be added to the initial treatment in areas with increased prevalence of methicillin-resistant Staphylococcus aureus (MRSA) or penicillin-resistant pneumococci.[2][3]
- The optimal duration of antimicrobial therapy is yet to be determined. Acute epiglottitis usually responds to a 7– to 10–day course of intravenous antibiotics.
Adjuvant Therapy
- Although adjuvant corticosteroids and racemic epinephrine are commonly used in the management of stridor associated with acute epiglottitis, neither of them were proved effective in reducing the need of airway intervention or shortening the hospitalization.[4]
Antimicrobial Regimens
- Epiglottitis[5]
- 1. Empiric antimicrobial therapy
- 1.1 Pediatrics
- Preferred regimen (1): Cefotaxime 50 mg/kg IV q8h
- Preferred regimen (2): Ceftriaxone 50–75 mg/kg/day IV q12–24h AND Vancomycin 10 mg/kg IV q6h
- Alternate regimen (1): Levofloxacin 500 mg IV q24h (or 8 mg/kg IV q12h) AND Clindamycin 20–40 mg/kg/day IV q6–8h
- 1.2 Adults
- Preferred regimen (1): Cefotaxime 2 g IV q4–8h
- Preferred regimen (2): Ceftriaxone 1–2 g/day IV q12–24h AND Vancomycin 2 g/day IV q6–12h
- Alternate regimen (1): Levofloxacin 750 mg IV q24h AND Clindamycin 600–1200 mg IV q6–12h
- 2. Pathogen-directed antimicrobial therapy
- 2.1 Streptococcus pneumoniae
- 2.2 Streptococcus pyogenes
- 2.3 Streptococcus agalactiae
- 2.4 Streptococcus anginosus
- 2.5 Staphylococcus aureus
- 2.6 Haemophilus influenzae
- 2.7 Klebsiella pneumoniae
- 2.8 Moraxella catarrhalis
- 2.9 Neisseria spp.
- 2.10 Pasteurella multocida
- 2.11 Pseudomonas aeruginosa
- 2.12 Candida albicans
Pathogen-Based Therapy
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ Streptococcus pneumoniae ▸ Streptococcus pyogenes ▸ Streptococcus agalactiae ▸ Streptococcus anginosus ▸ Staphylococcus aureus ▸ Haemophilus influenzae ▸ Klebsiella pneumoniae ▸ Moraxella catarrhalis ▸ Neisseria spp. ▸ Pasteurella multocida ▸ Pseudomonas aeruginosa Fungi ▸ Candida albicans |
|
References
- ↑ Kessler A, Wetmore RF, Marsh RR (1993). "Childhood epiglottitis in recent years". Int J Pediatr Otorhinolaryngol. 25 (1–3): 155–62. PMID 8436460.
- ↑ Alcaide ML, Bisno AL (2007). "Pharyngitis and epiglottitis". Infect Dis Clin North Am. 21 (2): 449–69, vii. doi:10.1016/j.idc.2007.03.001. PMID 17561078.
- ↑ Loftis L (2006). "Acute infectious upper airway obstructions in children". Semin Pediatr Infect Dis. 17 (1): 5–10. doi:10.1053/j.spid.2005.11.003. PMID 16522499.
- ↑ Frantz TD, Rasgon BM, Quesenberry CP (1994). "Acute epiglottitis in adults. Analysis of 129 cases". JAMA. 272 (17): 1358–60. PMID 7933397.
- ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.